Physician profile
Raymond Scott Douglas
NPI 1124041959
$1,266,619.84
in general payments reported to CMS, 2019-2025
9 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $372K · 2021: $329K · 2022: $235K · 2023: $210K · 2024: $21.68 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $111K · Consulting Fee: $53K · Honoraria: $38K · Travel and Lodging: $8,193 · Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $111,285.34 |
| Consulting Fee | $52,800.00 |
| Honoraria | $38,388.00 |
| Travel and Lodging | $8,193.25 |
| Food and Beverage | $1,707.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,248,579.71 | 2019-2023 | Tepezza |
| Vertical Pharmaceuticals, LLC | $15,050.00 | 2020 | |
| Kedrion Biopharma, INC. | $2,253.40 | 2025 | Kedrab, Koate, Gammaked |
| Allergan, INC. | $310.98 | 2020-2022 | |
| Genentech USA, INC. | $143.65 | 2022 | |
| Galderma Laboratories, L.P. | $143.48 | 2020 | |
| Stryker Corporation | $84.03 | 2019 | |
| Amgen INC. | $54.24 | 2024-2025 | Tepezza |
| Travere Therapeutics, INC. | $0.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.